<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336640">
  <stage>Registered</stage>
  <submitdate>7/03/2011</submitdate>
  <approvaldate>22/03/2011</approvaldate>
  <actrnumber>ACTRN12611000301965</actrnumber>
  <trial_identification>
    <studytitle>Immunomodulatory effect of anaesthetic technique in breast cancer surgery</studytitle>
    <scientifictitle>Comparison of T-lymphocyte function between propofol-remifentanil and sevoflurane anaesthesia in the breast cancer surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>breast cancer</healthcondition>
    <healthcondition>partial mastectomy with sentinel lymph node dissection</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>general anaesthesia with propofol 3 microg/ml, remifentanil 2 ng/ml in air (1 L/min) delivered at the same time with  oxygen (1L/min) mixture and continuously maintained with propofol 3 microg/ml, remifentanil 2 ng/ml in air (1 L/min)  delivered at the same time with oxygen  (1L/ min) mixture during operation (approximately 90-120 minutes)</interventions>
    <comparator>general anaesthesia with sevoflurane 1-2 minimum alveolar concentration in air (1 L/min) delivered at the same time with oxygen (1L/min) mixture and continuously maintained with sevoflurane 1-2 minimum alveolar concentration in air (1 L/min) delivered at the same time with oxygen (1L/min) mixture during operation (approximately 90-120 minutes)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>regulatory T cell subset(CD4/CD25/FoxP3) in peripheral blood will be evaluated using flow cytometry after monoclonal antibody staining</outcome>
      <timepoint>before anaesthetic induction, before discharge from the post anaesthesia care unit (PACU), 24 hour after end of operation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>activated T-cell panel (CD4/CD8/CD69/CTLA4) in peripheral blood will be evaluated using flow cytometry after monoclonal antibody staining</outcome>
      <timepoint>before anaesthetic induction, before discharge from the post anaesthesia care unit (PACU), 24 hour after end of operation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>dose of vaso-active drugs</outcome>
      <timepoint>during operation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>pain-scale  (0-10 visual analogue scale score)</outcome>
      <timepoint>before discharge from the PACU, 24 hour after end of operation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>dose of the pain killer drug</outcome>
      <timepoint>before discharge from the PACU, 24 hour after end of operation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>hospital complications including wound problem and elevated temperature will be assessed clinically</outcome>
      <timepoint>from end of operation until discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>American society of anesthesiologists physical status (ASA) I or II and scheduled for partial mastectomy with sentinel lymph node dissection due to breast cancer</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>elevated white blood cell count, eleveted body temperature, elevated c-reactive protein, liver cirrhosis, uncontrolled DM, uncontrolled HT, medication with steroid or non-steroidal anti-inflammatory drug</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>28/03/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Jie Ae Kim</primarysponsorname>
    <primarysponsoraddress>50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Samsung Medical Center Clinical Research Development Program grant, CRS110-07-1</fundingname>
      <fundingaddress>50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Eun Sook Gang</sponsorname>
      <sponsoraddress>50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</sponsoraddress>
      <sponsorcountry>Korea, Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will compare T-lymphocyte function including regulatory T cell subset (CD4/CD25/FoxP3) and activated T cell panel (CD4/CD8/CD69/CTLA4) and postoperative pain score and complications between propofol-remifentail and sevoflurane anaesthesia in patients undergoing partial mastectomy with sentinel lymph node dissection due to breast cancer. 
Sixty ASA 1-2 patients undergoing elective parial mastectomy with sentinel lymph node dissection will be randomly assigned into propofol-remifentanil or sevoflurane anaesthesia.  Anaesthetic depth will be monitored with BIS with target ranges between 30-60. Blood pressure and heart rate will be maintained within 20 % of preoperative values. The administered vaso-active drugs will be recorded. Peripheral venous blood will be obtained before anaesthetic induction, before discharge from the post anaesthesia care unit, and 24 hour after end of operation and will be analyzed for regulated T-cell subset (CD4/CD25/FoxP3) and activated T cell panel(CD4/CD8/CD69/CTLA4).  Postoperative pain scale score (0-10) and complications will be also evaluated.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional review board</ethicname>
      <ethicaddress>50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</ethicaddress>
      <ethicapprovaldate>1/08/2010</ethicapprovaldate>
      <hrec>2009-06-009-005</hrec>
      <ethicsubmitdate />
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</address>
      <phone>82-2-3410-0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</address>
      <phone>82-2-3410-0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</address>
      <phone>82-2-3410-0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>